Differential effect of hypoxia on etoposide-induced DNA damage response and p53 regulation in different cell types

Journal of Cellular Physiology

Volumn 228, Issue 12, 2013, Pages 2365-2376

  Sermeus, Audrey ^a   Rebucci, Magali ^a   Fransolet, Maude ^a   Flamant, Lionel ^a   Desmet, Déborah ^a   Delaive, Edouard ^a   Arnould, Thierry ^a   Michiels, Carine ^a  

^a University of Namur   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CHECKPOINT KINASE 2; ETOPOSIDE; HISTONE H2AX; LACTATE DEHYDROGENASE; PROTEIN MDM2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ACTIVATION; CELL DEATH; CELL FRACTIONATION; CELL HYPOXIA; CELL STRAIN HEPG2; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA BINDING; DNA DAMAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

APOPTOSIS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; CHECKPOINT KINASE 2; DNA DAMAGE; ETOPOSIDE; HEP G2 CELLS; HISTONES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTEOLYSIS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84882980158     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24409     Document Type: Article

References (51)

1. An WG, Chuman Y, Fojo T, Blagosklonny MV. 1998. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation. Exp Cell Res 244:54-60.
2. Antoni L, Sodha N, Collins I, Garrett MD. 2007. CHK2 kinase: Cancer susceptibility and cancer therapy-Two sides of the same coin? Nat Rev Cancer 7:925-936.
3. Bai J, Cederbaum AI. 2003. Catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents by accelerating the degradation of p53. J Biol Chem 278:4660-4667.
4. Bai J, Cederbaum AI. 2006. Cycloheximide protects HepG2 cells from serum withdrawal-induced apoptosis by decreasing p53 and phosphorylated p53 levels. J Pharmacol Exp Ther 319:1435-1443.
5. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM. 2005. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 65:11597-11604.
6. Bourdon JC. 2007. p53 and its isoforms in cancer. Br J Cancer 97:277-282.
7. Bristow RG, Hill RP. 2008. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8:180-192.
8. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, Lieberman J. 2005. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell 20:801-809.
9. Cosse JP, Sermeus A, Vannuvel K, Ninane N, Raes M, Michiels C. 2007. Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol Cancer 6:61.
10. Cosse JP, Ronvaux M, Ninane N, Raes MJ, Michiels C. 2009. Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia 11:976-986.
11. Flugel D, Gorlach A, Michiels C, Kietzmann T. 2007. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 27:3253-3265.
12. Foray N, Marot D, Gabriel A, Randrianarison V, Carr AM, Perricaudet M, Ashworth A, Jeggo P. 2003. A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. Embo J 22:2860-2871.
13. Gonen H, Shkedy D, Barnoy S, Kosower NS, Ciechanover A. 1997. On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett 406:17-22.
14. Hammond EM, Giaccia AJ. 2005. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 331:718-725.
15. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144:646-674.
16. Helton ES, Chen X. 2007. p53 modulation of the DNA damage response. J Cell Biochem 100:883-896.
17. Herrera-Merchan A, Cerrato C, Luengo G, Dominguez O, Piris MA, Serrano M, Gonzalez S. 2010. miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle 9:3277-3285.
18. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu Rev Biochem 67:425-479.
19. Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS, Tang LH, Levine AJ, Feng Z. 2010. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 38:689-699.
20. Jungmichel S, Stucki M. 2010. MDC1: The art of keeping things in focus. Chromosoma 119:337-349.
21. Karni-Schmidt O, Zupnick A, Castillo M, Ahmed A, Matos T, Bouvet P, Cordon-Cardo C, Prives C. 2008. p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. J Cell Sci 121:4098-4105.
22. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. 2002. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem 277:16547-16552.
23. Kisselev AF, Goldberg AL. 2001. Proteasome inhibitors: From research tools to drug candidates. Chem Biol 8:739-758.
24. Koumenis C, Wouters BG. 2006. " Translating" tumor hypoxia: Unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res 4:423-436.
25. Kubbutat MH, Vousden KH. 1997. Proteolytic cleavage of human p53 by calpain: A potential regulator of protein stability. Mol Cell Biol 17:460-468.
26. Lee JT, Gu W. 2010. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 17:86-92.
27. Lee JH, Paull TT. 2007. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 26:7741-7748.
28. Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. 2004. Hypoxia-inducible factor (HIF-1)alpha: Its protein stability and biological functions. Exp Mol Med 36:1-12.
29. Macurek L, Lindqvist A, Voets O, Kool J, Vos HR, Medema RH. 2010. Wip1 phosphatase is associated with chromatin and dephosphorylates gammaH2AX to promote checkpoint inhibition. Oncogene 29:2281-2291.
30. Meek DW. 2009. Tumour suppression by p53: A role for the DNA damage response? Nat Rev Cancer 9:714-723.
31. Montecucco A, Biamonti G. 2007. Cellular response to etoposide treatment. Cancer Lett 252:9-18.
32. Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, Michiels C. 2003. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem 278:31277-31285.
33. Pariat M, Carillo S, Molinari M, Salvat C, Debussche L, Bracco L, Milner J, Piechaczyk M. 1997. Proteolysis by calpains: A possible contribution to degradation of p53. Mol Cell Biol 17:2806-2815.
34. Piret JP, Cosse JP, Ninane N, Raes M, Michiels C. 2006. Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. Exp Cell Res 312:2908-2920.
35. Ray PS, Grover R, Das S. 2006. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 7:404-410.
36. Sermeus A, Michiels C. 2011. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2:e164.
37. Sermeus A, Cosse JP, Crespin M, Mainfroid V, de Longueville F, Ninane N, Raes M, Remacle J, Michiels C. 2008. Hypoxia induces protection against etoposide-induced apoptosis: Molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer 7:27.
38. Soubeyrand S, Pope L, Hache RJ. 2010. Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure. Mol Oncol 4:38-51.
39. Speidel D. 2010. Transcription-independent p53 apoptosis: An alternative route to death. Trends Cell Biol 20:14-24.
40. Stommel JM, Wahl GM. 2005. A new twist in the feedback loop: Stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4:411-417.
41. Stracker TH, Usui T, Petrini JH. 2009. Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) 8:1047-1054.
42. Sullivan R, Graham CH. 2009. Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Ther 8:1702-1713.
43. Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L'Etoile N, Goga A. 2010. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 16:1134-1140.
44. Thevenin D, Lazarova T, Roberts MF, Robinson CR. 2005. Oligomerization of the fifth transmembrane domain from the adenosine A2A receptor. Protein Sci 14:2177-2186.
45. Tian S, Huang S, Wu S, Guo W, Li J, He X. 2010. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 3' untranslated region. Biochem Biophys Res Commun 396:435-439.
46. Tsvetkov P, Reuven N, Shaul Y. 2010. Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ 17:103-108.
47. Vilborg A, Wilhelm MT, Wiman KG. 2010. Regulation of tumor suppressor p53 at the RNA level. J Mol Med 88:645-652.
48. Wilson KA, Stern DF. 2008. NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway. Cell Cycle 7:3584-3594.
49. Yang DQ, Halaby MJ, Zhang Y. 2006. The identification of an internal ribosomal entry site in the 5'-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 25:4613-4619.
50. Zhao Q, Guo HH, Wang Y, Washabaugh MW, Sitrin RD. 2005. Visualization of discrete L1 oligomers in human papillomavirus 16 virus-like particles by gel electrophoresis with Coomassie staining. J Virol Methods 127:133-140.
51. Zhou J, Schmid T, Schnitzer S, Brune B. 2006. Tumor hypoxia and cancer progression. Cancer Lett 237:10-21.